Discovery of Dual Chemotherapy Drug Candidates Designed by Molecular Hybridization

Current Enzyme Inhibition

Volumn 6, Issue 4, 2010, Pages 171-182

  do Couto Maia, Rodolfo ^a   Fraga, Carlos Alberto Manssour ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Chemotherapeutic agents; Chemotherapy; Drug resistance; Hybrid therapy; Molecular hybridization

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; 2 PYRIDONE DERIVATIVE; AMIDINOHYDRAZONE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTILEISHMANIAL AGENT; ANTIVIRUS AGENT; APLYSINOPSIN; BENANOMICIN A; BENZNIDAZOLE; BRAZILIZONE A; BRAZILIZONE N; CIPROFLOXACIN; DELAVIRDINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPEREZOLID; FRAMYCETIN; GENTAMICIN; KETOCONAZOLE; LINEZOLID; MADURAHYDROXYLACTONE; NIFURTIMOX; OXAZOLIDINONE DERIVATIVE; PENTAMIDINE; PRADIMICIN A; TERBINAFINE; UNCLASSIFIED DRUG;

ACETYLATION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CHAGAS DISEASE; CHEMOTHERAPY; COMPETITIVE INHIBITION; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME MODIFICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IC 50; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR HYBRIDIZATION; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PHARMACOPHORE; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; STREPTOCOCCUS PNEUMONIAE; TRYPANOSOMA; VIRUS RESISTANCE; VISCERAL LEISHMANIASIS;

BACTERIA (MICROORGANISMS);

EID: 79954442213     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340810794578515     Document Type: Review

References (55)

1. Kitagawa, H.; Ozawa, T.; Takahata, S.; Iida, M.; Saito, J.; Yamada, M. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK. J. Med. Chem., 2007, 50, 4710-4720.
2. Wang, J; Huang, J.; Wu, Y.; Hai, L.; Wang, G. Design and synthesis of novel thioether-linked carbapenem-oxazolidinone hybrids as potential antimicrobial agents. Lett. Org. Chem., 2008, 5, 336-341.
3. Charifson, P.S.; Grillot, A.; Grossman, T.H.; Parsons, J.D.; Badia, M.; Bellon, S.; Deininger, D.D.; Drumm, J.E.; Gross, C.H.; LeTiran, A.; Liao, Y.; Mani, N.; Nicolau, D.P.; Perola, E.; Ronkin, S.; Shannon, D.; Swenson, L.L.; Tang, Q.; Tessier, P.R.; Tian, S.; Trudeau, M.; Wang, T.; Wei, Y.; Zhang, H.; Stamos, D. Novel dual-targeting benzimidazole urea inhibitors of dna gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structureguided design and structure-activity relationships. J. Med. Chem., 2008, 51, 5243-5263.
4. Barreiro, E.J.; Fraga, C.A.M. New insights for multifactorial disease therapy: The challenge of the symbiotic drugs. Curr. Drug Ther., 2008, 3, 1-13.
5. Bremmer, J.B.; Ambrus, J.I.; Samosorn, S. Dual action-based approaches to antibacterial agents. Curr. Med. Chem., 2007, 14, 1459-1477.
6. Morphy, R.; Rankovic, Z. Designed multiple ligands. an emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
7. Pokrovskaya, V.; Belakhov, V.; Hainrichson, M.; Yaron, S.; Baasov, T. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. J. Med. Chem., 2009, 52, 2243-2254.
8. Viegas-Junior, C.; Danuello, A.; Bolzani, V.S.; Barreiro, E.J.; Fraga, C.A.M. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr. Med. Chem., 2007, 14, 1829-1852.
9. Fraga, C.A.M. Drug hybridization strategies: Before or after lead identification? Exp. Opin. Drug Discov., 2009, 4, 605-609.
10. Magnet, S.; Blanchard, J.S. Molecular insights into aminoglycoside action and resistance. Chem. Rev., 2005, 105, 477-498.
11. Benveniste, R.; Davies, J. aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria. Proc. Natl. Acad. Sci. USA, 1973, 70, 2276-2280.
12. Hawkey, P.M. Mechanisms of quinolone action and microbial response. J. Antimicrob. Chemother., 2003, 51 (Suppl. 1), 29-35.
13. Zimmer, C.; Triebel, H.; Thrum, H. Interaction of streptothricin and related antibiotics with nucleic acids. Biochim. Biophys. Acta., 1967, 145, 742-751.
14. Fung, H.B.; Kirschenbaum, H.L.; Ojofeitimi, B.O. Linezolid: an oxazolidinone antimicrobial agent. Clin. Ther., 2001, 23, 356-391.
15. Tsiodras, S.; Gold, H.S.; Sakoulas, G.; Eliopoulos, G.M.; Wennersten, C.; Venkataraman, L.; Moellering, R.C. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet, 2001, 358, 207-208.
16. Gordeev, M.F.; Hackbarth, C.; Barbachyn, M.R.; Banitt, L.S.; Gage, J.R.; Luehr, G.W.; Gomez, M.; Trias, J.; Morin, S.E.; Zurenko, G.E.; Parker, C.N.; Evans, J.M.; White, R.J.; Patel, D.V. Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg. Med. Chem. Lett., 2003, 13, 4213-4216.
17. Hubschwerlen, C.; Specklin, J-L.; Sigwalt, C.; Schroeder, S.; Locher, H.H. Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids. Bioorg. Med. Chem., 2003, 11, 2313-2319.
18. Heath, R.J.; Rock, C.O. Inhibition of graphic-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli. J. Biol. Chem., 1996, 271, 10996-11000.
19. Takahata, S.; Iida, M; Osaki, Y.; Saito, J.; Kitagawa, H.; Ozawa, T.; Yoshida, T.; Hoshiko, S. AG205, a novel agent directed against FabK of Streptococcus pneumonia. Antimicrob. Agents. Chemother., 2006, 50, 2869-2871.
20. Kitagawa, H.; Kumura, K.; Takahata, S.; Iida, M.; Atsumi, K. 4- Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI. Bioorg. Med. Chem., 2007, 15, 1106-1116.
21. Li, J.; Tan, Z.; Tang, S.; Hewlett, I.; Pang, R.; He, M.; He, S.; Tian, B.; Chen, K.; Yang, M. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid. Bioorg. Med. Chem., 2009, 17, 3177-3188.
22. Girouard, M.; Diallo, K.; Marchand, B.; McCormick, S.; Götte, M. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC. J. Biol. Chem., 2003, 278, 34403-34410.
23. Yeni, P. Update on HAART in HIV. J. Hepatol., 2006, 44(Suppl), S100-S103.
24. Chesney, M. Adherence to HAART Regimens. AIDS Patient Care ST., 2003, 17, 169-177.
25. Zhang, D.W.; Huang, P.L.; Lee-Huang, S.; Zhang, J.Z.H. Design of hybrid inhibitors to HIV-1 protease. J. Theor. Comput. Chem., 2008, 7, 485-503.
26. Goldgur, Y.; Dyda, F.; Hickman, A.B.; Jenkins, T.M.; Craigie, R.; Davies, D.R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. USA, 1998, 95, 9150-9154.
27. Telesnitsky, A.; Goff, S.P. Reverse transcriptase and the generation of viral DNA. In RetroViruses; Coffin, J.M., Hughes, S.H., Varmus, H.E., Eds.; Cold Spring Harbor Laboratory Press: Plainview, NY, 1997; pp 121-160.
28. Andréola, M. Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease h and integrase: Killing two birds with one stone. Curr. Pharm. Des., 2004, 10, 3713-3723.
29. Wang, Z.; Vince, R. Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine. Bioorg. Med. Chem., 2008, 16, 3587- 3595.
30. Billamboz, M.; Bailly, F.; Barreca, M.L.; De Luca, L.; Mouscadet, J-F.; Calmels, C.; Marie-Line Andréola, M-L.; Witvrouw, M.; Christ, F.; Debyser, Z.; Cotelle, P. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J. Med. Chem., 2008, 51, 7717-7730.
31. Takeuchi, T.; Hara, T.; Naganawa, H.; Okada, M.; Hamada, M.; Umezawa, H.; Gomi, S.; Sezaki, M.; Kondo, S. New antifungal antibiotics, benanomicins A and B from an actinomycete. J. Antibiot. (Tokyo), 1988, 41, 807- 811.
32. Oki, T.; Tenmyo, O.; Hirano, M.; Tomatsu, K.; Kamei, H. Pradimicins A, B and C: new antifungal antibiotics. J. Antibiot. (Tokyo), 1990, 43, 763-770.
33. Marchand, C.; Beutler, J.A.; Wamiru, A.; Budihas, S.; Möllmann, U.; Heinisch, L.; Mellors, J.W.; Le Grice, S.F.; Pommier, Y. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 Integrase and RNase H. Antimicrob. Agents Chemother., 2008, 52, 361-364.
34. Cavalli, M.; Bolognesi, M.L. Neglected tropical diseases: Multitarget- directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J. Med. Chem., 2009, 52, 7339-7359.
35. Butler, D. Lost in translation. Nature, 2007, 449, 158-159.
36. Hotez, P.J.; Molyneux, D.H.; Fenwick, A.; Kumaresan, J.; Sachs, S.E.; Sachs, J.D.; Savioli, L. Control of neglected tropical diseases. N. Engl. J. Med., 2007, 357, 1018-1027.
37. Paulino, M.; Iribarne, F.; Dubin, M.; Aguilera-Morales, S.; Tapia, O.; Stoppani, A.O. The Chemotherapy of Chagas' disease: An overview. Mini-Rev. Med. Chem., 2005, 5, 499-519.
38. Vermelho, A.B.; De Simone, S.G.; d'Avila-Levy, C.M.; Santos, A.L.S.; Melo, A.C.N.; Silva-Junior, F.P.; Bon, E.P.S.; Branquinha, M.H. Trypanosomatidae peptidases: A Target for drug development. Curr. Enzyme Inhib., 2007, 3, 19-48.
39. Bryceson, A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health, 2001, 6, 928-934.
40. Porwal, S.; Chauhan, S.S.; Chauhan, P.M.S.; Shakya, N.; Verma, A.; Gupta, S. Discovery of novel antileishmanial agents in an attempt to synthesize pentamidine-aplysinopsin hybrid molecule. J. Med. Chem., 2009, 52, 5793-5802.
41. Fan, X.; Feng, D.; Qu, Y.; Zhang, X.; Wang, J.; Loiseau, P.M.; Andrei, G.; Snoeck, R.; De Clercq, E. Practical and efficient synthesis of pyrano[3,2-c]pyridone, pyrano[4,3-b]pyran and their hybrids with nucleoside as potential antiviral and antileishmanial agents. Bioorg. Med. Chem., 2010, 20, 809-813.
42. De Clercq, E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. II Farmaco, 1999, 54, 26-45.
43. Kemnitzer, W.; Kasibhatla, S.; Jiang, S.; Zhang, H.; Zhao, J.; Jia, S.; Xu, L.; Crogan-Grundy, C.; Denis, R.; Barriault, N.; Vaillancourt, L.; Charron, S.; Dodd, J.; Attardo, G.; Labrecque, D.; Lamothe, S.; Gourdeau, H.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8- positions. Bioorg. Med. Chem. Lett., 2005, 15, 4745-4751.
44. Chen, I.S.; Wu, S.J.; Tsai, I.L.; Wu, T.S.; Pezzuto, J.M.; Lu, M.C.; Chai, H.; Suh, N.; Teng, C.M. Chemical and bioactive constituents from Zanthoxylum simulans. J. Nat. Prod., 1994, 57, 1206-1211.
45. Du, X.; Gui, C.; Hansell, E.; Doyle, P.S.; Caffrey, C.R.; Holler, T.P.; McKerrow, J.H.; Cohen, F.E. Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem., 2002, 45, 2695-2707.
46. Porcal, W.; Hernández, P.; Aguirre, G.; Boiani, L.; Boiani, M.; Merlino, A.; Ferreira, A.; DiMaio, R.; Castro, A.; González, M.; Cerecetto, H. Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and structure-activity relationships. Bioorg. Med. Chem., 2007, 15, 2768-2781.
47. Porcal, W.; Hernández, P.; Boiani, L.; Boiani, M.; Ferreira, A.; Chidichimo, A.; Cazzulo, J.J.; Olea-Azar, C.; González, M.; Cerecetto, H. New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. Bioorg. Med. Chem., 2008, 16, 6995-7004.
48. Carvalho, S.A.; Silva, E.F.; Santa-Rita, R.M.; Castro, S.L.; Fraga, C.A.M. Synthesis and antitrypanosomal profile of new functionalized 1,3,4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorg. Med. Chem. Lett., 2004, 14, 5967-5970.
49. Carvalho, S.A.; Lopes, F.A.S.; Salomão, K.; Romeiro, N.C.; Wardell, S.M. S.V.; Castro, S.L.; Silva, E.F.; Fraga, C.A.M. Studies toward the structural optimization of new brazilizone-related trypanocidal 1,3,4-thiadiazole-2-aryl hydrazone derivatives. Bioorg. Med. Chem. Lett., 2008, 16, 413-421.
50. Filardi, L.S.; Brener, Z. A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections. Ann. Trop. Med. Parasitol., 1982, 76, 293-297.
51. Messeder, J.C.; Tinoco, L.W.; Figueroa-Villar, J.D.; Souza, E.M.; Santa Rita, R.; de Castro, S.L. Aromatic guanyl hydrazones: Synthesis, structural studies and in vitro activity against Trypanosoma cruzi. Bioorg. Med. Chem. Lett., 1995, 5, 3079-3084.
52. Fraga, C.A.M., unpublished results.
53. Van Tyle, J.H. Ketoconazole: Mechanism of action, spectrum of activity, pharmacokinetics, drug interations, adverse reactions and therapeutic use. Pharmacotheraphy., 1984, 4, 343-373.
54. Konter, J.; Möllmann, U.; Lehmann, J. NO-donors. Part 17: Synthesis and antimicrobial activity of novel ketoconazole-NO-donor hybrid compounds. Bioorg. Med. Chem., 2008, 16, 8294-8300.
55. He, Q.; Leitch, G.J.; Visvesvara, G.S.; Wallace, S. Effects of nifedipine, metronidazole, and nitric oxide donors on spore germination and cell culture infection of the microsporidia Encephalitozoon hellem and Encephalitozoon intestinalis. Antimicrob. Agents Chemother., 1996, 40, 179-185.